Preventing Invasive Pneumococcal Disease in Children & Adolescents with Leukaemia

Phase 3

Active, not recruiting

• Conditions: Immunogenicity of pneumococcal vaccination in children and adolescents newly diagnosed with Leukaemia, with the aim to protect them from invasive pneumococcal disease; Cancer - Leukaemia - Acute leukaemia

• Registration Number: ACTRN12609000515291
• Lead Sponsor: HMRC CCRE in Childhood and Adolescent Immunisation

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2009-06-29
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Active, not recruiting
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

All children receiving therapy for Leukaemia (Acute Lymphoblastic Leukaemia (ALL) or Acute Myeloblastic leukaemia (AML)) will potentially be eligible for inclusion. Diagnoses are confirmed histopathologically according to national and international guidelines

Exclusion Criteria

Exclusion criteria will include those children who suffer a relapse or have a Bone Marrow Transplant. If a study subject relapses following commencement of the study they will be excluded from further participation. Patients will not be vaccinated until their blood count is satisfactory: platelets>/= 50 x109/L and neutrophils>/=500 x 106/L. Recent immunoglobulin (within last 9 months) or previous severe adverse reaction to vaccinations will also be exclusion criteria as per the Australian Immunisation guidelines.

Study & Design

• Study Type: Interventional
• Study Design: Not specified